

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

Mouse Anti-Human ER alpha (F-10) Monoclonal, Unconjugated, Clone F-10

RRID:AB_627558

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-8002, RRID:AB_627558

Antibody Information

URL: http://antibodyregistry.org/AB_627558

Proper Citation: Santa Cruz Biotechnology Cat# sc-8002, RRID:AB_627558

Target Antigen: Human ESR1

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown check with seller; recommendations: ELISA; Immunocytochemistry; Immunofluorescence; Immunohistochemistry; Immunoprecipitation; Western Blot; Western Blotting, Immunoprecipitation, Immunofluorescence, Immunohistochemistry(P), ELISA

Antibody Name: Mouse Anti-Human ER alpha (F-10) Monoclonal, Unconjugated, Clone F-10

Description: This monoclonal targets Human ESR1

Target Organism: human

Clone ID: F-10

Antibody ID: AB_627558

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-8002

Record Creation Time: 20250820T063441+0000

Record Last Update: 20250821T002802+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-Human ER alpha (F-10) Monoclonal, Unconjugated, Clone F-10.

No alerts have been found for Mouse Anti-Human ER alpha (F-10) Monoclonal, Unconjugated, Clone F-10.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 33 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Song J, et al. (2026) 3D post-implantation co-culture of human embryo and endometrium. Cell stem cell, 33(1), 58.

Shemorry A, et al. (2025) Engineering ER α degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases. Cell chemical biology, 32(5), 694.

Olsen SN, et al. (2025) Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer. Cell reports. Medicine, 6(7), 102192.

Zhu J, et al. (2025) FGD3 mediates lytic cell death, enhancing efficacy and immunogenicity of chemotherapy agents in breast cancer. Journal of experimental & clinical cancer research : CR, 44(1), 299.

Mogol AN, et al. (2025) ACSS2-Mediated Metabolic-Epigenetic Crosstalk Drives Fulvestrant Resistance and Represents a Novel Therapeutic Target. bioRxiv : the preprint server for biology.

Ndjim M, et al. (2024) Tuft cell acetylcholine is released into the gut lumen to promote anti-helminth immunity. Immunity, 57(6), 1260.

Rona G, et al. (2024) CDK-independent role of D-type cyclins in regulating DNA mismatch repair. Molecular cell.

Chen X, et al. (2024) Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostate. Nature communications, 15(1), 10675.

Zhang Z, et al. (2024) Oestrogen promotes the progression of adenomyosis by inhibiting CITED2 through miR-145. Reproductive biomedicine online, 49(6), 104108.

Hosseinzadeh L, et al. (2024) The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer. *Genome biology*, 25(1), 44.

Psaltis JB, et al. (2024) Cadmium activation of wild-type and constitutively active estrogen receptor alpha. *Frontiers in endocrinology*, 15, 1380047.

Diep CH, et al. (2024) Progesterone Receptor Signaling Promotes Cancer Associated Fibroblast Mediated Tumorigenicity in ER+ Breast Cancer. *Endocrinology*, 165(9).

Fang Z, et al. (2023) Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis. *Nature communications*, 14(1), 7725.

Pan M, et al. (2023) Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degradar for Breast Cancer Therapy. *Cancer research communications*, 3(7), 1378.

Chattopadhyay M, et al. (2022) The portrait of liver cancer is shaped by mitochondrial genetics. *Cell reports*, 38(3), 110254.

Wang Y, et al. (2022) TXNIP Links Anticipatory Unfolded Protein Response to Estrogen Reprogramming Glucose Metabolism in Breast Cancer Cells. *Endocrinology*, 163(1).

Qureshi R, et al. (2022) Estrone, the major postmenopausal estrogen, binds ERα to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis. *Cell reports*, 41(7), 111672.

Ng ASN, et al. (2022) AKTIP loss is enriched in ER⁺-positive breast cancer for tumorigenesis and confers endocrine resistance. *Cell reports*, 41(11), 111821.

Yun J, et al. (2022) ER⁺ inhibits mesenchymal and amoeboidal movement of liver cancer cell via G⁺12. *International journal of cancer*, 150(10), 1690.

Shin EM, et al. (2021) GREB1: An evolutionarily conserved protein with a glycosyltransferase domain links ER⁺ glycosylation and stability to cancer. *Science advances*, 7(12).